The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Very interesting RNS this morning...
"JV relating to the exploration of other minerals (except for gold and base metals) within the licence area.".
Post on ADVFN by The Count links the Lionstown Lithium block which is directly next door to MILA's:
"Highly likely they are talking about Lithium, as this is what the license was first explored for, the license is also close to LTR's giant Lithium project . LTR are subject to a 5.5b takeover approach"
Now imagine that...!! If that is truly the case, then wow- MILA and its 3.5m market cap could go crazy if that's confirmed.
"...we are hopeful that we can provide full details of a potential transaction in the coming weeks." ... Exciting times!
No mention of VLS at all, not good. I suspect a few who were in for that gamble may well leave now.
Good day today- and a news rich period ensues with various updates due to be revealed, this will be much much higher in the coming months. Just topped up.
Safe to say it's nothing to do with RDGC in any way :)
Mologic have some excellent technology for LFDs. Mainly their CARD sector and something that is unique to them, so it's not like Avacta could have had this tech themselves or with anybody else:
https://mologic.co.uk/mologic-achieves-breakthrough-in-ultra-sensitive-point-of-care-diagnostics-and-develops-new-platform-technology/
This is what Avacta have combined with their affimers which has allowed them to get down to the 50pg/ml figure for the test that we will see first. It's a relatively new link this between Mologic and Avacta, so they will have the first gen test which is the Avacta AffiDX Spike Protein test, and then in the future they have outlined they will produce the Next Gen' Hybrid test which will test for both S & N proteins.
Okay. So current deal is for 70,000 schools, each with roughly around 200 students in. An extremely lowball estimate of a yearly subscription from each of those schools is £2000 a year. That's £140m a year revenue just from those 70k schools, and profit from that is likely to be 80-90% based on other SAAS type deals. DEV's market cap is £65m. Then if you take into account the potential 240k extra schools, and the further market beyond that of the public schools of 1m+ you start to get to some silly numbers (even with the extremely low £2k a year subscription figure).
A £1billion market cap isn't as daft as it sounds. Can see DEV being £2+ in 2021.
The prospectus being released soon will hopefully give an idea on subscription figures, and once that's out- it's go time.
Interesting Avacta are listed as the rapid antigen saliva test they’re looking at? I think ODX may be asked to manufacture as many as they possibly can for Avacta and the government.
Have you seen the address of BBI solutions, the first signed up manufacturer/validation partner??
BBI Solutions – Salisbury, UK
Address: Porton Science Park Incubator Centre, Bybrook Road, Porton Down, Salisbury, Wiltshire, SP4 0BF.